{{Rsnum
|rsid=12721608
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Orientation=plus
|Orientation=plus
|Chromosome=3
|position=119811572
|Gene=NR1I2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene_s=NR1I2
}}{{PharmGKB
|RSID=rs12721608
|Name_s=NR1I2: PXR*4; R122Q; 4321G>A
|Gene_s=NR1I2
|Feature=Exon/NonSyn
|Evidence=PubMed ID:11668216
|Annotation=The variant NR1I2 R122Q protein had significantly decreased affinity for the PXR binding sequence in electromobility shift assays. In a transient transfection assays this SNP showed attenuated ligand activation of the CYP3A4 reporter plasmids. The study reports that the person heterozygous for PXR*4 is normal for CYP3A4 metabolism phenotype.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162356083
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}